

PROGRAMME

QRW Programme Cancer Biology Programme 28 August – 29 August, 2016 Rutherford Hotel, Nelson, New Zealand

Sunday 28 August		
Time	Details	Location
<u>Past, Present and Future of Cancer Biology</u> Chaired by Annette Lasham (University of Auckland)		
9.00am – 9.10am	Introduction: Annette Lasham University of Auckland	Maitai 2
9.10am – 10.00am	Bruce Baguley (CB1) Sponsored by Abcam University of Auckland, Auckland <i>Cancer in four dimensions</i>	Maitai 2
10.00am – 10.30am	Morning tea	Maitai 1
<u>Past, present and future of Cancer Biology</u> Chaired by – Antony Braithwaite (University of Otago)		
10.30am – 10.55am	Vernon Harvery (CB2) Oncology161 <i>How to Improve the Outcome of Breast Cancer A Clinician's Perspective</i>	Maitai 2
10.55am – 11.15am	Christopher Jackson (CB3) University of Otago <i>ORAXOL: New Zealand's role in the development of a novel oral chemotherapy agent</i>	Maitai 2
11. 15am – 11.40am	Sean Grimmond (CB4) University of Melbourne <i>Decoding challenging cancers</i>	Maitai 2
11.40am – 12.05pm	Parry Guilford (CB5) Sponsored by Roche University of Otago <i>Hereditary Diffuse Gastric Cancer: battling the curse</i>	Maitai 2
12.05pm – 12.30pm	Rod Dunbar (CB6) Sponsored by In Vitro Technologies University of Auckland <i>Targeting T cells to cancer antigens</i>	Maitai 2
12.30pm – 1.30pm	Lunch	Maitai 1
<u>Cell Signalling and Tumour Microenvironment</u> Chaired by Peter Shepherd (University of Auckland)		
1.30pm – 2.00pm	Paul Timpson (CB7) Garvan Institute of Medical Research <i>Transient tissue 'priming' via ROCK manipulation uncouples pancreatic cancer progression, chemo-</i>	Maitai 2

	<i>resistance and the onset of the metastatic niche: insights from intravital biosensor imaging</i>	
2.00pm – 2.20pm	Wanjin Hong (CB8) Sponsored by Beckman Coulter NZ Ltd Institute of Molecular and Cell Biology, A-Star, Singapore <i>TAZ/YAP and their partners in the Hippo pathway</i>	Maitai 2
2.20pm – 2.40pm	Antony Braithwaite (CB9) University of Otago <i>IL-6 signalling mediates tumorigenesis, invasion and metastasis driven by the $\Delta 133p53$ isoform</i>	Maitai 2
2.40pm – 2.55pm	Tania Slatter (CB10) University of Otago <i>Surgical success and response to adjuvant therapy in glioblastoma depends on telomere maintenance associated markers</i>	Maitai 2
2.55pm – 3.10pm	Marina Kazantseva (CB11) University of Otago <i>Investigating the association of $\Delta 133p53$ isoform expression and the inflammatory microenvironment in prostate tumours</i>	Maitai 2
3.10pm – 3.20pm	Andrew Bahn (CB12) University of Otago <i>Changes in cellular uric acid homeostasis facilitated by Glucose Transporter 9 (GLUT9) drive activin sensitivity and prostate cancer cell behaviour</i>	Maitai 2
3.20pm – 3.30pm	Christina Molck (CB13) University of Melbourne <i>Quantification of spatio-temporal correlations of interacting cells using a new statistical approach – Colorectal cancer cells used as a model system</i>	Maitai 2
3.30pm – 4.00pm	Afternoon Tea	Maitai 1
<u>Cancer Immunotherapy – Joint session with Drug Discovery Satellite</u> Chaired by – Rod Dunbar (University of Auckland)		
4.00pm – 4.20pm	Ian Hermans (CB14/ DD12) Sponsored by Thermo Fisher Scientific Malaghan Institute, Victoria University of Wellington <i>Helping cancer vaccines</i>	Maitai 2
4.20pm – 4.40pm	Gavin Painter (CB15/DD13) Victoria University of Wellington, Ferrier Institute <i>Bioorthogonal synthesis and antitumour activity of CD1d dependent glycolipid-peptide vaccines</i>	Maitai 2
4.40pm – 5.00pm	David Larsen (CB16/DD14) University of Otago <i>Synthesis and Activity of 6''-Deoxy-6''-Thio-α-GalCer and Peptide Conjugates</i>	Maitai 2
5.00pm – 5.20pm	Sarah Young (CB17/DD15) Sponsored by Beckman Coulter NZ Ltd University of Otago	Maitai 2

	<i>Enhancing immune therapies for cancer</i>	
5.20pm – 5.40pm	Bridget Stocker (CB18/DD16) Victoria University of Wellington <i>Trehalose Glycolipids: 'Upping the Ante'</i>	Maitai 2
5.40pm – 5.50pm	Kaveesha Bodiyaudu (CB19) University of Auckland <i>Characterisation of circular RNA in melanoma cell lines</i>	Maitai 2
5:50pm – 6:00pm	Lydia Liew (CB20/DD18) University of Auckland <i>Small molecule modulators of the adrenomedullin 1 receptor</i>	Maitai 2
6.00pm – 7.30pm	Poster Session	Maitai 2
7.30pm	End of conference session for the day	Maitai 2
8:00pm	Conference Dinner Coaches depart the Rutherford Lobby at 7.45pm sharp.	The Styx

Monday 29 August		
Time	Details	Location
<u>Joint Plenary Lecture</u> Chaired by Peter Shepherd		
8.00am – 8.30am	Roger Williams (CB21/DD17) MRC Laboratory of Molecular Biology, Cambridge <i>Structural adaptations of Class III PI3K and a PIKK to regulate cellular homeostasis</i>	Maitai 2
<u>Pre-clinical Models</u> Chaired by Antony Braithwaite (University of Auckland)		
8.30am – 8.50am	Tony Cesare (CB22) Children's Medical Research Institute <i>DNA replication stress induces mitotic cell death through the telomere DNA damage response and cohesion failure</i>	Maitai 2
8.50am – 9.00am	Sunali Mehta (CB23) University of Otago <i>Role of YB-1 in cell cycle</i>	Maitai 2
9.00am – 9.10 am	Catherine Drummond (CB24) St. Jude Childrens Research Hospital <i>Insights into the origins and pathogenesis of embryonal rhabdomyosarcoma</i>	Maitai 2
9:10am – 9:20am	Jisha Antony (CB25) University of Otago <i>Targeting cohesion mutant myeloid leukaemias</i>	Maitai 2
9:20am – 9:30am	Rhea Desai (CB26) University of Auckland <i>Characterization of CALM-AF10 induced leukaemia in a murine bone marrow transplantation model</i>	Maitai 2
9:30am – 9:40am	David Herrmann (CB27) Garvan Institute of Medical Research <i>Predicting cancer spread before it happens</i>	Maitai 2

9:40am – 9:50am	Stephen Jamieson (CB28) University of Auckland <i>Patient derived and cell line xenograft models of head and neck cancer for preclinical testing of hypoxia activated prodrugs</i>	Maitai 2
9.50am – 10.00am	Kathryn Burns (CB29) University of Auckland <i>5-Fluorouracil uptake in human gastrointestinal cancers</i>	Maitai 2
10.00am – 10.30am	Morning tea	Maitai 1
<u>Current Molecular Tools and Resources for Cancer</u> Chaired by – Sarah Young (University of Otago)		
10.30am – 11.00am	Marco Herold (CB30) Walter + Eliza Hall Institute of Medical Research <i>Using CRISPR/Cas9 methodology to identify and validate novel cell death regulators for cancer therapy</i>	Maitai 2
11.00am – 11.30am	Karen Mann (CB31) Sponsored by NeSI, NZGL & REANNZ Houston Methodist Research Institute, Houston <i>Sleeping Beauty uncovers cooperating driver genes in a preclinical mouse model of myeloid leukaemia</i>	Maitai 2
11.30am – 11.45am	Sonja Frolich (CB32) University of Adelaide <i>Development of automated high-content microscopy-assisted assays for telomere biology</i>	Maitai 2
11.45am – 12.00pm	Amanda Capes-Davis (CB33) Cell Bank Australia <i>Materials Matter: Authenticating cell lines for cancer research</i>	Maitai 2
12.00pm – 12.10pm	Sean Warren (CB34) Garvan Institute of Medical Research <i>Simultaneous visualisation of RhoA and Rac1 activation using multi-spectral FLIM</i>	Maitai 2
12.10pm – 12.20pm	James Conway (CB35) Garvan Institute of Medical Research <i>Targeting chemoresistance within the hypoxic microenvironment of pancreatic cancer</i>	Maitai 2
12.20pm – 12.30pm	David Croucher (CB36) Garvan Institute of Medical Research <i>Dissecting ERBB2 signalling complexes in breast cancer by Bimolecular Complementation Affinity Purification (BiCAP)</i>	Maitai 2
12.30pm – 1.30pm	Lunch	Maitai 1
<u>Cancer Genomics</u> Chaired by – Mike Eccles (University of Otago)		
1.30pm – 2.00pm	Simon Barry (CB37)	Maitai 2

	University of Adelaide <i>Mapping enhancer networks by chromatin conformation capture</i>	
2.00pm – 2.20pm	Mik Black (CB38) University of Otago <i>Bioinformatic analysis of insertional mutagenesis data from Sleeping Beauty mouse models of cancer</i>	Maitai 2
2.20pm – 2.40pm	Aniruddha Chatterjee (CB39) University of Otago <i>A framework and example for identifying epigenetic drivers of cancer metastasis</i>	Maitai 2
2.40pm – 3.00pm	Ben Lawrence (CB40) University of Auckland <i>Cancer clinic post human genome: working in progress</i>	Maitai 2
3.00pm – 3.10pm	Nicholas Fleming (CB41) University of Otago <i>A common variation within the IL6 promoter may alter its control by the p53 protein family and influence cancer progression</i>	Maitai 2
3.10pm – 3.20pm	Rachel Purcell (CB42) University of Otago, Christchurch <i>Bacterial dysbiosis and the development of colorectal cancer</i>	Maitai 2
3.20pm – 3.30pm	George Wiggins (CB43) University of Otago, Christchurch <i>Gene expression variability in breast tumours</i>	Maitai 2
3.30pm – 4.00pm	Afternoon Tea	Maitai 1
Translational Research Chaired by – Parry Guilford (University of Otago)		
4.00pm – 4.30pm	Colleen Nelson (CB44) Queensland University of Technology <i>Characterising the adaptive response to androgen targeted therapies highlights mechanisms of resistance and opportunities for novel therapeutics approaches</i>	Maitai 2
4.30pm – 4.50pm	Glen Reid (CB45) Sponsored by Beckman Coulter NZ Ltd University of Sydney <i>Clinical development of TargomiRs, a microRNA mimic-based treatment for patients with malignant pleural mesothelioma</i>	Maitai 2
4.50pm – 5.05pm	Tim Strabala (CB46) Environmental Protection Authority <i>New Zealand's first GMO release: Pexa-Vec, for liver cancer therapy clinical trials</i>	Maitai 2
5:05pm – 5:30pm	Cristin Print (CB47) Sponsored by Medi'Ray University of Auckland	Maitai 2

	<i>Looking into the future: how far could genomics and bioinformatics go to help cancer patients?</i>	
5:30pm	Conference closes	Maitai 2